Articles tagged with Depressants
Researchers at UH College of Pharmacy are developing breakthroughs to combat sepsis, a leading cause of hospital deaths, and diseases such as Alzheimer's and sickle cell disease. A dual-action nanomedicine has shown a 100% survival rate in preclinical trials for sepsis treatment.
A cohort study of over 1.8 million Canadian adults found that shorter prescription courses, single medication, and short-acting agents are associated with lower rates of long-term benzodiazepine use. This study provides valuable insights for informing prescribing practices to reduce reliance on these medications.
A randomized trial found that duloxetine does not prevent painful neuropathy caused by oxaliplatin-based chemotherapy in patients with stage II or III colorectal cancer. The study suggests that duloxetine should only be used for managing existing neuropathy, not prevention.
A new study found that new psychoactive substances (NPS) are a significant concern in roadway crashes in California. NPS, also known as ‘designer drugs’, were detected in the blood of 17 patients, with most frequent being designer benzodiazepines and fentanyl analogs.
A new study found that initial prescriptions of benzodiazepines for older stroke survivors often include excessive doses, posing a risk of dependence, falls, and other harmful effects. Guidelines recommend avoiding benzodiazepine prescriptions if possible, but some cases may require limited use under close monitoring.
The study data show that Procizumab promptly restored cardiac dysfunction in a preclinical sepsis model by inhibiting the cardiac depressant factor DPP3. The administration of Procizumab improved heart function by increasing cardiac output, stroke volume, and left ventricular shortening fraction.